Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN41,9342,09-0,19
Msft0,62
Nokia3,58853,6-0,14
IBM0,21
Daimler AG48,1948,211,03
PFE2,00
24.10.2020 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 23.10.2020 18:35:11
Medigene N (Frankfurt)
Závěr k 23.10.2020 Změna (%) Změna (EUR) Objem obchodů (EUR)
3,64 3,26 0,12 4 303
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 25.10.2020
Popis společnosti
Obecné informace
Název společnostiMediGene AG
TickerMDG1
Kmenové akcie:Ordinary Shares
RICMDG1k.DE
ISINDE000A1X3W00
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 30.06.2020 136
Akcie v oběhu k 30.06.2020 24 562 658
MěnaEUR
Kontaktní informace
UliceLochhamer Strasse 11
MěstoPLANEGG
PSČ82152
ZeměGermany
Kontatní osobaJulia Hofmann
Funkce kontaktní osobyInvestor & Public Relations Contact Officer
Telefon49 892 000 330
Fax49892000332920
Kontatní telefon49892 000 333 301

Business Summary: Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Financial Summary: BRIEF: For the three months ended 30 June 2020, MediGene AGrevenues decreased 60% to EUR2.3M. Net loss decreased 39%to EUR5.9M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Lower net loss reflects Research anddevelopment expenses decrease of 51% to EUR5.3M (expense),Selling expenses decrease of 75% to EUR211K (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 25.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardHorst Domdey6716.07.201316.07.2013
Chairman of the Executive Management Board, Chief Executive Officer, Chief Scientific OfficerDolores Schendel-01.02.201601.05.2014
Deputy Chairman of the Supervisory BoardAntoinette Hiebeler-Hasner6011.08.201611.08.2016
Chief Financial Officer and Chief Business Development OfficerAxel-Sven Malkomes-01.04.201901.04.2019
Member of the Executive Management Board, Chief Medical Officer, Chief Development OfficerKai Pinkernell-11.04.2018